OTCMKTS:MAGAA

Magna-Lab Competitors

$1.02
0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.02
Now: $1.02
$1.02
50-Day Range
$1.02
MA: $1.45
$2.50
52-Week Range
$0.11
Now: $1.02
$2.00
VolumeN/A
Average Volume3,117 shs
Market Capitalization$1.20 million
P/E Ratio5.67
Dividend YieldN/A
Beta5.2

Competitors

Magna-Lab (OTCMKTS:MAGAA) Vs. NIMU, RSLSD, NXNN, ARDMQ, ECTE, and IMRSQ

Should you be buying MAGAA stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Magna-Lab, including Non-Invasive Monitoring Systems (NIMU), ReShape Lifesciences (RSLSD), Nexeon MedSystems (NXNN), Aradigm (ARDMQ), Echo Therapeutics (ECTE), and IMRIS (IMRSQ).

Magna-Lab (OTCMKTS:MAGAA) and Non-Invasive Monitoring Systems (OTCMKTS:NIMU) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Risk and Volatility

Magna-Lab has a beta of 5.2, suggesting that its share price is 420% more volatile than the S&P 500. Comparatively, Non-Invasive Monitoring Systems has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500.

Profitability

This table compares Magna-Lab and Non-Invasive Monitoring Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Magna-LabN/A-12.32%42,399.99%
Non-Invasive Monitoring SystemsN/A-2,509.09%-80.19%

Earnings and Valuation

This table compares Magna-Lab and Non-Invasive Monitoring Systems' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Magna-LabN/AN/A$-130,000.00N/AN/A
Non-Invasive Monitoring SystemsN/AN/A$-160,000.00N/AN/A

Analyst Recommendations

This is a breakdown of current recommendations for Magna-Lab and Non-Invasive Monitoring Systems, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Magna-Lab0000N/A
Non-Invasive Monitoring Systems0000N/A

Summary

Magna-Lab beats Non-Invasive Monitoring Systems on 4 of the 4 factors compared between the two stocks.

Magna-Lab (OTCMKTS:MAGAA) and ReShape Lifesciences (OTCMKTS:RSLSD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Risk and Volatility

Magna-Lab has a beta of 5.2, suggesting that its share price is 420% more volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Magna-Lab and ReShape Lifesciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Magna-Lab0000N/A
ReShape Lifesciences0000N/A

Profitability

This table compares Magna-Lab and ReShape Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Magna-LabN/A-12.32%42,399.99%
ReShape Lifesciences-668.58%-163.22%-52.10%

Earnings and Valuation

This table compares Magna-Lab and ReShape Lifesciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Magna-LabN/AN/A$-130,000.00N/AN/A
ReShape Lifesciences$610,000.000.00$-81,150,000.00N/AN/A

Magna-Lab has higher earnings, but lower revenue than ReShape Lifesciences.

Summary

Magna-Lab beats ReShape Lifesciences on 5 of the 6 factors compared between the two stocks.

Nexeon MedSystems (OTCMKTS:NXNN) and Magna-Lab (OTCMKTS:MAGAA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability.

Profitability

This table compares Nexeon MedSystems and Magna-Lab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nexeon MedSystemsN/AN/AN/A
Magna-LabN/A-12.32%42,399.99%

Earnings and Valuation

This table compares Nexeon MedSystems and Magna-Lab's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nexeon MedSystemsN/AN/AN/AN/AN/A
Magna-LabN/AN/A$-130,000.00N/AN/A

Volatility and Risk

Nexeon MedSystems has a beta of 12.71, indicating that its stock price is 1,171% more volatile than the S&P 500. Comparatively, Magna-Lab has a beta of 5.2, indicating that its stock price is 420% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Nexeon MedSystems and Magna-Lab, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nexeon MedSystems0000N/A
Magna-Lab0000N/A

Summary

Nexeon MedSystems beats Magna-Lab on 2 of the 3 factors compared between the two stocks.

Aradigm (OTCMKTS:ARDMQ) and Magna-Lab (OTCMKTS:MAGAA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Volatility & Risk

Aradigm has a beta of 2.91, meaning that its share price is 191% more volatile than the S&P 500. Comparatively, Magna-Lab has a beta of 5.2, meaning that its share price is 420% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Aradigm and Magna-Lab, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aradigm0000N/A
Magna-Lab0000N/A

Earnings and Valuation

This table compares Aradigm and Magna-Lab's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AradigmN/AN/AN/AN/AN/A
Magna-LabN/AN/A$-130,000.00N/AN/A

Profitability

This table compares Aradigm and Magna-Lab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AradigmN/AN/AN/A
Magna-LabN/A-12.32%42,399.99%

Summary

Magna-Lab beats Aradigm on 2 of the 3 factors compared between the two stocks.

Echo Therapeutics (OTCMKTS:ECTE) and Magna-Lab (OTCMKTS:MAGAA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Profitability

This table compares Echo Therapeutics and Magna-Lab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Echo TherapeuticsN/AN/AN/A
Magna-LabN/A-12.32%42,399.99%

Analyst Ratings

This is a breakdown of current ratings for Echo Therapeutics and Magna-Lab, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Echo Therapeutics0000N/A
Magna-Lab0000N/A

Risk and Volatility

Echo Therapeutics has a beta of 7.09, suggesting that its stock price is 609% more volatile than the S&P 500. Comparatively, Magna-Lab has a beta of 5.2, suggesting that its stock price is 420% more volatile than the S&P 500.

Valuation and Earnings

This table compares Echo Therapeutics and Magna-Lab's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Echo TherapeuticsN/AN/AN/AN/AN/A
Magna-LabN/AN/A$-130,000.00N/AN/A

Summary

Echo Therapeutics beats Magna-Lab on 2 of the 3 factors compared between the two stocks.

IMRIS (OTCMKTS:IMRSQ) and Magna-Lab (OTCMKTS:MAGAA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Risk and Volatility

IMRIS has a beta of -10.69, suggesting that its stock price is 1,169% less volatile than the S&P 500. Comparatively, Magna-Lab has a beta of 5.2, suggesting that its stock price is 420% more volatile than the S&P 500.

Valuation and Earnings

This table compares IMRIS and Magna-Lab's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMRISN/AN/AN/AN/AN/A
Magna-LabN/AN/A$-130,000.00N/AN/A

Profitability

This table compares IMRIS and Magna-Lab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IMRISN/AN/AN/A
Magna-LabN/A-12.32%42,399.99%

Analyst Ratings

This is a breakdown of current ratings for IMRIS and Magna-Lab, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IMRIS0000N/A
Magna-Lab0000N/A

Summary

Magna-Lab beats IMRIS on 2 of the 3 factors compared between the two stocks.


Magna-Lab Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
NIMU
Non-Invasive Monitoring Systems
0.5$0.03flat$2.69 millionN/A0.00Upcoming Earnings
RSLSD
ReShape Lifesciences
0.4N/AN/A$1.94 million$610,000.000.00High Trading Volume
Nexeon MedSystems logo
NXNN
Nexeon MedSystems
0.7$0.55flat$1.12 millionN/A0.00Gap Down
ARDMQ
Aradigm
0.0$0.05flat$764,000.00N/A0.00
Echo Therapeutics logo
ECTE
Echo Therapeutics
0.5$0.03flat$359,000.00N/A0.00
IMRIS logo
IMRSQ
IMRIS
0.5$0.01flat$312,000.00N/A0.00
SCIE
SpectraScience
0.5$0.00flat$265,000.00N/A0.00
ULGX
Urologix
0.6$0.01flat$192,000.00N/A0.00Gap Up
AKSY
Aksys
0.0$0.00flat$0.00N/A0.00
Escalon Medical logo
ESMC
Escalon Medical
0.5$0.35flat$0.00$9.40 million-5.83
HRTT
Heart Tronics
0.0$0.15flat$0.00N/A0.00
IVVI
Ivivi Technologies
0.0$0.00flat$0.00N/A0.00High Trading Volume
NWCI
NewCardio
0.5$0.00flat$0.00N/A0.00
PECN
Photoelectron
0.2$0.03flat$0.00N/A0.00
Trimedyne logo
TMED
Trimedyne
0.4$4.25flat$0.00$5.57 million0.00
XCRP
Xcorporeal
0.0$0.00flat$0.00N/A0.00
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.